Document is current

Article History

Received: 30 July 2022

Accepted: 19 November 2022

First Online: 8 December 2022

Declarations

:

: This multicenter study has Ethics approval from the Melbourne Health Human Research Ethics Committee (HREC/17/Mh/115).

: The ethics approval included the waiver for consent to participation and publication based on:

: James Broadley, Robb Wesselingh, Udaya Seneviratne, Chris Kyndt, Paul Beech, Katherine Buzzard, Richard Macdonell, and Cassie Nesbitt report no disclosures.Wendyl D’Souza’s salary is part-funded by The University of Melbourne. He has received travel, investigator-initiated, scientific advisory board and speaker honoraria from UCB Pharma Australia and Global; investigator-initiated, scientific advisory board, travel and speaker honoraria from Eisai Australia and Global; advisory board honoraria from Liva Nova; educational grants from Novartis Pharmaceuticals, Pfizer Pharmaceuticals and Sanofi-Synthelabo; educational; travel and fellowship grants from GSK Neurology Australia, and honoraria from SciGen Pharmaceuticals.Amy Brodtmann is on the editorial boards for Neurology and International Stroke Journal, and an Australian Scientific Advisory Board for Biogen.Tomas Kalincik served on scientific advisory boards for Roche, Celgene, Sanofi-Genzyme, Novartis, Merck and Biogen, steering committee for Brain Atrophy Initiative by Sanofi-Genzyme, received conference travel support and/or speaker honoraria from WebMD Global, Novartis, Biogen, Sanofi-Genzyme, Teva, BioCSL and Merck and received research support from Biogen.Terence J. O’Brien receives research funding from Biogen, UCB Pharma, Eisai Pharma, Anavex Pharmaceuticals, Zynerba Pharmaceuticals, and serves on the scientific advisory boards for UCB Pharma, Eisai Pharmaceuticals, Zynerba Pharmaceuticals, ES Therapeutics, Seqirus Pharmaceuticals.Helmut Butzkueven’s institution receives funding from Biogen, Roche, Merck and Novartis for speaker engagements, study steering and advisory committee service. He is on the editorial board of Multiple Sclerosis and Related Disorders and the Steering committee of the Brain Health Initiative (Oxford Health Policy Forum).Mastura Monif’s institution and research is supported from the National Health and Medical Research Council (Medical Research Future Fund), MS Research Australia, Bethlehem Griffith Foundation, Charles and Sylvia Viertel Foundation, and Merck. Mastura has served on the scientific advisory board of Merck.